The Faculty of Medicine together and the Turku PET Centre hosted visitors from the radiopharmaceutical company Curium Pharma to showcase research and innovation in Turku region.
On 9 September 2025, the University of Turku hosted a delegation from Curium Pharma, a leading global radiopharmaceutical company, for a full-day visit showcasing the region’s research and innovation strengths. The visit was organised by the Faculty of Medicine and the Turku PET Centre, in close cooperation with BioCity Turku, MediCity and Turku University Hospital/the well-being services county of Southwest Finland.
The seven-person Curium team, with representatives arriving from London, Helsinki, Brussels, Rome, Philadelphia and Boston, was introduced to Turku’s world-class expertise in GMP radiochemistry, preclinical and clinical imaging, clinical integration and translational drug and diagnostics research. Presentations covered topics from novel tracer development and theranostic applications to AI-supported ligand design, animal disease models and pathways from research to business.
At the Turku PET Centre, Curium representatives engaged with experts in radiopharmaceutical innovation and toured GMP facilities and clinical scanners. Afternoon sessions highlighted the broader life science ecosystem, including BioCity Turku’s translational research programmes, MediCity’s industry collaboration pathways and regional support from Business Turku.
The visit is part of growing discussions around potential collaboration in drug and diagnostic innovation, aligned with the Translational Doctorates in Drug and Diagnostic Innovation (T3DI) COFUND programme, where Curium is an Associate Partner.
Feedback from Curium was highly positive:
“The programme gave us a comprehensive view of the Turku PET Centre, the University and the wider ecosystem. The discussions were insightful and stimulating, and my team came away with a strong sense of both the breadth of capability in Turku and the potential areas where we could explore collaboration,” said Ben Burke, Director of Early Stage Development at Curium.
The University of Turku and its partners look forward to further strengthening cooperation with Curium in the development of next-generation radiopharmaceuticals and theranostics.
